ID   ICLU-E
AC   CVCL_E8UB
RX   PubMed=10405829;
CC   Group: Hybridoma fusion partner cell line.
CC   Group: Serum/protein free medium cell line.
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_63486; 8-azaguanine.
CC   Selected for resistance to: ChEBI; CHEBI_9555; Tioguanine (6-thioguanine; 6-TG).
CC   Sequence variation: Gene fusion; HGNC; HGNC:19124; FIP1L1 + HGNC; HGNC:8803; PDGFRA; Name(s)=FIP1L1-PDGFRA (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C4563; Chronic eosinophilic leukemia, not otherwise specified
DI   ORDO; Orphanet_168940; Chronic eosinophilic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0258 ! EoL-1
SX   Male
AG   33Y
CA   Cancer cell line
DT   Created: 14-08-25; Last updated: 14-08-25; Version: 1
//
RX   PubMed=10405829; DOI=10.3233/HAB-1999-9202;
RA   Kawahara, Hiroharu
RA   Maeda-Yamamoto, Mari
RA   Suzuki, Makiko
RA   Hakamata, Katsuhiro
RT   "New human fusion partners, ICLU-B, -T, -E for making human hybridomas
RT   derived from various immunological cells.";
RL   Hum. Antibodies 9:89-94(1999).
//